Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.8 CHF | +0.43% | -0.98% | +39.10% |
Apr. 26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
Sales 2023 | 96.72M 105M 94.63M | Sales 2024 * | 262M 284M 256M | Capitalization | 1.16B 1.26B 1.13B |
---|---|---|---|---|---|
Net income 2023 | 1M 1.08M 978K | Net income 2024 * | 111M 120M 109M | EV / Sales 2023 | 8.6 x |
Net cash position 2023 | 48.44M 52.53M 47.39M | Net cash position 2024 * | 110M 119M 108M | EV / Sales 2024 * | 4.01 x |
P/E ratio 2023 |
771
x | P/E ratio 2024 * |
9.93
x | Employees | 319 |
Yield 2023 |
3.65% | Yield 2024 * |
2.91% | Free-Float | 44.36% |
Latest transcript on Cosmo Pharmaceuticals N.V.
1 day | +0.43% | ||
1 week | -0.98% | ||
1 month | -2.07% | ||
3 months | +5.51% | ||
6 months | +65.61% | ||
Current year | +39.10% |
Managers | Title | Age | Since |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chairman | 61 | 05-12-31 | |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 96-12-31 | |
Director/Board Member | 69 | 12-03-31 | |
Chairman | 61 | 05-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 746 M€ | -.--% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 70.8 | +0.43% | 26,123 |
24-05-30 | 70.5 | -0.70% | 12,986 |
24-05-29 | 71 | -0.28% | 9,891 |
24-05-28 | 71.2 | -1.39% | 12,392 |
24-05-27 | 72.2 | +0.98% | 5,555 |
Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.10% | 1.26B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- COPN Stock